홈
마켓
차트 & 아이디어
Algo
뉴스
Store
브로커
다운로드
경제 달력
트레이딩 시그널
웹터미널
Heatmap
검색
/
타입: @user, $symbol
검색
로그인
계정을 생성하십시오
한국어
English
Русский
中文
Español
Português
日本語
Deutsch
Français
Italiano
Türkçe
ACIU
#3289
AC Immune SA
3.1
9
USD
-3.33%
부문:
헬스케어
베이스:
USD
수익 통화:
USD
일일 변동 비율
년간 변동
일일 변동
-3.33%
월간 변동
+6.69%
6달 변화
+6.33%
년간 변동율
+105.81%
이전 종가
3.3
0
Open
3.1
9
Bid
Ask
Low
3.1
9
High
3.1
9
양
17
마켓
주식
헬스케어
ACIU
Open full chart
Financials
Overview
성명
Statistics
Quarterly
Annual
Value
2020
2021
2022
2023
2024
2025
TTM
Key stats
Total common shares outstanding
71.94 M
83.48 M
83.62 M
99.2 M
100.41 M
101.74 M
384.97 M
Valuation ratios
Enterprise value
371.91 M
413.22 M
184.8 M
465.24 M
271.11 M
319.47 M
1.24 B
Price to earnings ratio
—
—
—
—
—
—
—
Price to sales ratio
—
—
—
—
—
—
—
Price to cash flow ratio
—
—
—
—
—
—
—
Price to book ratio
—
—
—
—
—
—
—
EBITDA 비율에 대한 기업 가치
—
—
—
—
—
—
—
Profitability ratios
Return on assets %
—
—
—
—
—
—
—
Return on equity %
—
—
—
—
—
—
—
Return on invested capital %
—
—
—
—
—
—
—
Gross margin %
—
—
—
—
—
—
—
Operating margin %
—
—
—
—
—
—
—
EBITDA margin %
—
—
—
—
—
—
—
Net margin %
—
—
—
—
—
—
—
Liquidity ratios
Quick ratio
—
—
—
—
—
—
—
Current ratio
—
—
—
—
—
—
—
Inventory turnover
—
—
—
—
—
—
—
Asset turnover
—
—
—
—
—
—
—
Solvency ratios
Debt to assets ratio
—
—
—
—
—
—
—
Debt to equity ratio
—
—
—
—
—
—
—
Long term debt to total assets ratio
—
—
—
—
—
—
—
Long term debt to total equity ratio
—
—
—
—
—
—
—
Per share metrics
Operating cash flow per share
—
—
—
—
—
—
—
EBIT per share
—
—
—
—
—
—
—
EBITDA per share
—
—
—
—
—
—
—
Total debt per share
—
—
—
—
—
—
—
Cash per share
—
—
—
—
—
—
—
Net current asset value per share
—
—
—
—
—
—
—
Tangible book value per share
—
—
—
—
—
—
—
Working capital per share
—
—
—
—
—
—
—
Book value per share
—
—
—
—
—
—
—
뉴스
ACIU Stock Rallies 16.3% in a Week: Here's What You Need to Know
Is AC Immune (ACIU) Stock Outpacing Its Medical Peers This Year?
AC Immune Stock FY 2025 Results: Eyeing ACI-7104 Catalysts (NASDAQ:ACIU)
Is AC Immune (ACIU) Outperforming Other Medical Stocks This Year?
AC Immune Q1 실적, 수익 에상치보다 저조
AC Immune earnings missed, revenue fell short of estimates
제퍼리스, AC Immune에 ’매수’ 등급 유지…백신 데이터 긍정적
Jefferies reiterates AC Immune stock Buy rating on vaccine data
AC Immune, 뇌 침투 NLRP3 억제제 1상 시험 개시
AC Immune begins phase 1 trial of brain-penetrant NLRP3 inhibitor
2026 Market Outlook: Focus On Pharma For Consistent Returns, Potential Skyrocketing Shares
AC Immune: Maintaining 'Buy' Rating On Next Steps For ACI-7104.056 Development In PD